This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

Take a closer look at your untreated PD-L1 ≥50% TPS mNSCLC patients

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland)
[External links]

Could KEYTRUDA® (pembrolizumab) monotherapy continue to transform treatment expectations for your untreated PD-L1 ≥50% TPS metastatic non-small cell lung cancer (mNSCLC) patients?1

Discover the exploratory 5 year follow-up analysis of KEYNOTE-024 in the document below.2

KEYTRUDA as monotherapy is indicated for the first-line treatment of metastatic non-small cell lung carcinoma (NSCLC) in adults whose tumours express PD-L1 with a ≥50% tumour proportion score (TPS) with no EGFR or ALK positive tumour mutations.3 The recommended dose of KEYTRUDA as monotherapy is either 200 mg every 3 weeks or 400 mg every 6 weeks administered as an intravenous infusion over 30 minutes.3

References

  1. Planchard D, et al. Ann Oncol. 2018:(Suppl 4);iv192–iv237. Available from: https://www.esmo.org/guidelines/lung-and-chest-tumours/clinical-practice-living-guidelines-metastatic-non-small-cell-lung-cancer.
  2. Reck M, et al. J Clin Oncol 2021; doi: 10.1200/JCO.21.00174. Online ahead of print.
  3. KEYTRUDA Summary of Product Characteristics and Prescribing Information.

Supporting documentation

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website

GB-PDO-01796 | Date of Preparation: October 2021